News | PET-MRI | November 08, 2018

Researcher Awarded 2018 Hitachi Healthcare Americas/RSNA Grant

 

 

David Schultz, M.D., Ph.D.

David Schultz, M.D., Ph.D.

The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded the 2018 Hitachi Healthcare Americas/RSNA Research Seed Grant to David Shultz, M.D., Ph.D. This grant is made possible by Hitachi Healthcare Americas’ support of the RSNA R&E Foundation. The Hitachi Healthcare Americas/RSNA Research Seed Grant provides $40,000 for a one-year project to test hypotheses and obtain pilot data in preparation for major grant applications. David Shultz, M.D., Ph.D., Princess Margaret Cancer Centre, with scientific advisor Patrick VeitHaibach, M.D., will use FAZA-PET/MRI to identify hypoxic tumor in patients with localized high-risk sarcoma. Dr. Shultz and his team will also use pimonidazole, a molecular probe for hypoxia, to validate the FAZA results and further characterize the biologic features of hypoxic tumors. The ultimate goal of this work is to determine if hypoxia imaging with PET/MRI improves the management of sarcoma and to evaluate and characterize hypoxic mechanisms on a molecular level within clinical specimens. Through these efforts, they seek to improve the ability to treat patients with high-risk sarcoma. The RSNA R&E Foundation Board of Trustees approved funding for $4 million in radiology research and education grants this year, achieving a funding rate of 35 percent of grant applicants. “The R&E Foundation is grateful for Hitachi Healthcare Americas’ support of the 2018 grant recipients. This longstanding partnership and commitment is a vital component in ensuring research innovation and seeding the future of radiology,” said N. Reed Dunnick, M.D., chair of the R&E Foundation Board of Trustees. 

For more information: www.rsna.org

Related Content

Philips Signs Agreement to Create Taiwan's First Fully Digitalized Pathology Department
News | Digital Pathology | August 23, 2019
Philips announced that Taipei Veterans General Hospital (TPVGH) will utilize the Philips IntelliSite Pathology Solution...
Glassbeam Introduces AI-powered Rules and Alerts Engine for Clinsights
News | Analytics Software | August 23, 2019
Glassbeam Inc. revealed several technology enhancements in its Rules & Alerts engine that make it dramatically...
Sectra Signs Enterprise Imaging Contract With Vanderbilt Health
News | Enterprise Imaging | August 21, 2019
Sectra will install its enterprise imaging picture archiving and communication system (PACS) and vendor neutral archive...
Vaping Impairs Vascular Function

Image courtesy of the American Heart Association

News | Magnetic Resonance Imaging (MRI) | August 21, 2019
Inhaling a vaporized liquid solution through an e-cigarette, otherwise known as vaping, immediately impacts vascular...
Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
ADHD Medication May Affect Brain Development in Children

Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al.

News | Neuro Imaging | August 16, 2019
A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...